Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients

AIDS

Volumn 26, Issue 14, 2012, Pages 1789-1794

  Hull, Mark W ^a   Rollet, Kathleen ^b   Moodie, Erica E M ^c   Walmsley, Sharon ^d   Cox, Joseph ^c,e   Potter, Martin ^f   Cooper, Curtis ^g   Pick, Neora ^a   Saeed, Sahar ^b   Klein, Marina B ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c Department of Epidemiology Biostatistics and Occupational Health ^*  (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MONTREAL GENERAL HOSPITAL   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

^g BC CHILDREN S HOSPITAL   (Canada)

Author keywords

coinfection; hepatic fibrosis; hepatitis C virus; HIV; insulin resistance

Indexed keywords

ARTICLE; BODY MASS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HEPATITIS C; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM;

ADULT; CANADA; COINFECTION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS C, CHRONIC; HIV SEROPOSITIVITY; HUMANS; INSULIN RESISTANCE; LIVER CIRRHOSIS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES;

EID: 84866337563     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835612ce     Document Type: Article

References (34)

1. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterol-ogy 2003; 125:1695-1704. (Pubitemid 37500434)
2. Harrison SA. Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment. Clin Gastroen-terol Hepatol 2008; 6:864-876.
3. Hedblad B, Nilsson P, Engstrom G, Berglund G, Janzon L. Insulin resistance in nondiabetic subjects is associated with increased incidence of myocardial infarction and death. Diabet Med 2002; 19:470-475. (Pubitemid 34639157)
4. Moller DE, Flier JS. Insulin resistance: mechanisms, syndromes, and implications. N Engl J Med 1991; 325:938-948.
5. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128:636-641. (Pubitemid 40585366)
6. Poustchi H, Negro F, Hui J, Cua IH, Brandt LR, Kench JG, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008; 48:28-34. (Pubitemid 350191982)
7. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concents in man. Diabetologia 1985; 28:412-419. (Pubitemid 15018832)
8. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54:1003-1008. (Pubitemid 40873917)
9. Howard AA, Lo Y, Floris-Moore M, Klein RS, Fleischer N, Schoenbaum EE. Hepatitis C virus infection is associated with insulin resistance among older adults with or at risk of HIV infection. AIDS 2007; 21:633-641.
10. Duong M, Petit JM, Piroth L, Grappin M, Buisson M, Chavanet P, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27:245-250. (Pubitemid 32661965)
11. Squillace N, Lapadula G, Torti C, Orlando G, Mandalia S, Nardini G, et al. Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: a cross-sectional study. HIV Med 2008; 9:151-159. (Pubitemid 351279572)
12. Merchante N, Macias J, Ramayo E, Vergara S, Garcia-Garcia JA, Mira JA, et al. Insulin resistance is not associated with liver fibrosis progression in HIV/hepatitis C virus-coinfected patients. J Viral Hepat 2006; 13:449-456.
13. Klein MB, Saeed S, Yang H, Cohen J, Conway B, Cooper C, et al. Cohort profile: the Canadian HIV-Hepatitis C Co-infection Cohort Study. Int J Epidemiol 2010; 39:1162-1169.
14. Al-Mohri H, Cooper C, Murphy T, Klein MB. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 2005; 6:375-378. (Pubitemid 41723304)
15. Nunes D, Fleming C, Offner G, O'Brien M, Tumilty S, Fix O, et al. HIV infection does not affect the performance of non-invasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 2005; 40:538-544. (Pubitemid 41669157)
16. Sanchez-Conde M, Montes-Ramirez ML, Miralles P, Alvarez JM, Bellon JM, Ramirez M, et al. Comparison of transient elasto-graphy and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat 2010; 17:280-286.
17. Halfon P, Penaranda G, Carrat F, Bedossa P, Bourliere M, Ouzan D, et al. Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients. Aliment Pharmacol Ther 2009; 30:61-70.
18. Vachon ML, Factor SH, Branch AD, Fiel MI, Rodriguez-Torres M, Brau N, et al. Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-alpha-2a and ribavirin in HIV/HCV co-infected patients. J Hepatol 2011; 54:41-47.
19. Al-Mohri H, Murphy T, Lu Y, Lalonde RG, Klein MB. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr 2007; 44:463-469. (Pubitemid 46555383)
20. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992; 340:925-929.
21. Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005; 19:1375-1383. (Pubitemid 41800673)
22. Tien PC, Schneider MF, Cole SR, Levine AM, Cohen M, De-Hovitz J, et al. Antiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV study. J Acquir Immune Defic Syndr 2008; 49:369-376.
23. Walli R, Herfort O, Michl GM, Demant T, Jager H, Dieterle C, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12:F167-F173. (Pubitemid 28479266)
24. Walmsley S, Cheung AM, Fantus G, Gough K, Smaill F, Azad A, et al. A prospective study of body fat redistribution, lipid, and glucose parameters in HIV-infected patients initiating combination antiretroviral therapy. HIV Clin Trials 2008; 9:314-323.
25. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-1713. (Pubitemid 37468321)
26. Macias J, Mira JA, Lopez-Cortes LF, Santos I, Giron-Gonzalez JA, Gonzalez-Serrano M, et al. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Antivir Ther 2006; 11:839-846. (Pubitemid 44736175)
27. Merchante N, Rivero A, de Los Santos-Gil I, Merino D, Marquez M, Lopez-Ruz MA, et al. Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients. Gut 2009; 58:1654-1660.
28. Merchante N, de los Santos-Gil I, Merino D, Gonzalez-Serrano M, Mira JA, Sanz-Sanz J, et al. Insulin resistance is not a relevant predictor of sustained virological response to pegylated inter-feron plus ribavirin in HIV/HCV co-infected patients. J Hepatol 2009; 50:684-692.
29. Ryan P, Resino S, Miralles P, Cosin J, Lopez JC, Moreno S, et al. Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus. J Acquir Immune Defic Syndr 2010; 55:176-181.
30. Valenti L, Pulixi E, Fracanzani AL, Dongiovanni P, Maggioni M, Orsatti A, et al. TNFalpha genotype affects TNFalpha release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. J Hepatol 2005; 43:944-950. (Pubitemid 41627978)
31. Persico M, Capasso M, Persico E, Svelto M, Russo R, Spano D, et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: insulin resistance and response to antiviral therapy. Hepatology 2007; 46:1009-1015. (Pubitemid 350144765)
32. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003; 38:1384-1392. (Pubitemid 37466964)
33. Eslam M, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Use of HOMA-IR in hepatitis C. J Viral Hepat 2011; 18:675-684.
34. Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 2011; 34:297-305.